Core Viewpoint - Devonian Health Group Inc. is actively engaging with institutional investors and has announced a non-brokered private placement to support its operations and research activities [1][4][5]. Group 1: Company Presentation - Dr. André Boulet, the Chairman and CEO of Devonian, will present at the ThinkEquity Conference on October 30, 2025 [1][8]. - The conference aims to connect institutional investors, analysts, and growth-oriented companies for presentations and networking [2]. Group 2: Private Placement Details - Devonian has completed a non-brokered private placement, raising gross proceeds of $334,500.33 through the issuance of 1,967,649 units at a price of $0.17 per unit [4][5]. - Each unit consists of one common share and one share purchase warrant, with the warrant allowing the purchase of one share at the same price for 24 months [4][6]. - The funds raised will primarily be allocated to working capital for corporate overhead and research and development activities [5]. Group 3: Regulatory and Financial Information - A cash finder's fee of $14,166.68 was paid in connection with the offering, and the issued shares and warrants are subject to a four-month hold period ending on February 23, 2026 [6]. - The offering is pending final approval from the TSX Venture Exchange [6].